$KALA
KALA BIO, Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008970 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $1.372M $3.266M
YoY Change -57.99% 204.95%
Cost Of Revenue $775.0K $760.0K
YoY Change 1.97% 117.14%
Gross Profit $597.0K $2.510M
YoY Change -76.22% 248.61%
Gross Profit Margin 43.51% 76.85%
Selling, General & Admin $26.98M $27.70M
YoY Change -2.59% 79.77%
% of Gross Profit 4519.6% 1103.55%
Research & Development $4.466M $3.126M
YoY Change 42.87% -42.47%
% of Gross Profit 748.07% 124.54%
Depreciation & Amortization $157.0K $248.0K
YoY Change -36.69% 7.83%
% of Gross Profit 26.3% 9.88%
Operating Expenses $32.29M $31.58M
YoY Change 2.24% 48.99%
Operating Profit -$30.91M -$28.31M
YoY Change 9.18% 40.69%
Interest Expense $2.035M $2.141M
YoY Change -4.95% 0.61%
% of Operating Profit
Other Income/Expense, Net -$2.027M
YoY Change
Pretax Income -$32.94M -$30.41M
YoY Change 8.32% 38.48%
Income Tax
% Of Pretax Income
Net Earnings -$32.94M -$30.41M
YoY Change 8.32% 38.52%
Net Earnings / Revenue -2400.95% -931.17%
Basic Earnings Per Share -$0.45 -$0.49
Diluted Earnings Per Share -$0.45 -$0.49
COMMON SHARES
Basic Shares Outstanding 73.64M 61.66M
Diluted Shares Outstanding 73.64M 61.66M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.16M $156.0M
YoY Change -55.02% -20.61%
Cash & Equivalents $65.17M $128.0M
Short-Term Investments $4.992M $28.00M
Other Short-Term Assets $4.542M $2.600M
YoY Change 74.69% -29.73%
Inventory $10.53M $8.241M
Prepaid Expenses
Receivables $13.02M $12.21M
Other Receivables $0.00 $0.00
Total Short-Term Assets $98.26M $179.1M
YoY Change -45.13% -14.81%
LONG-TERM ASSETS
Property, Plant & Equipment $2.704M $3.042M
YoY Change -11.11% -90.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.230M $19.20M
YoY Change -51.93% 17.07%
Total Long-Term Assets $13.32M $50.76M
YoY Change -73.76% 5.1%
TOTAL ASSETS
Total Short-Term Assets $98.26M $179.1M
Total Long-Term Assets $13.32M $50.76M
Total Assets $111.6M $229.8M
YoY Change -51.45% -11.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.218M $2.855M
YoY Change 117.79% 137.92%
Accrued Expenses $21.24M $15.15M
YoY Change 40.2% -5.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.76M $19.99M
YoY Change 63.88% 15.54%
LONG-TERM LIABILITIES
Long-Term Debt $79.36M $72.52M
YoY Change 9.43% 1.57%
Other Long-Term Liabilities $4.739M $27.50M
YoY Change -82.77% -2.83%
Total Long-Term Liabilities $84.10M $100.0M
YoY Change -15.94% 0.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.76M $19.99M
Total Long-Term Liabilities $84.10M $100.0M
Total Liabilities $116.9M $120.0M
YoY Change -2.65% 2.59%
SHAREHOLDERS EQUITY
Retained Earnings -$575.3M -$430.2M
YoY Change 33.74%
Common Stock $73.00K $64.00K
YoY Change 14.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.284M $109.8M
YoY Change
Total Liabilities & Shareholders Equity $111.6M $229.8M
YoY Change -51.45% -11.09%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$32.94M -$30.41M
YoY Change 8.32% 38.52%
Depreciation, Depletion And Amortization $157.0K $248.0K
YoY Change -36.69% 7.83%
Cash From Operating Activities -$24.09M -$32.64M
YoY Change -26.2% 64.19%
INVESTING ACTIVITIES
Capital Expenditures -$81.00K -$220.0K
YoY Change -63.18% -24.14%
Acquisitions
YoY Change
Other Investing Activities -$4.992M $48.25M
YoY Change -110.35%
Cash From Investing Activities -$5.073M $48.03M
YoY Change -110.56% -16548.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.71M
YoY Change -73.45%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 154.0K 35.32M
YoY Change -99.56% -73.08%
NET CHANGE
Cash From Operating Activities -24.09M -32.64M
Cash From Investing Activities -5.073M 48.03M
Cash From Financing Activities 154.0K 35.32M
Net Change In Cash -29.01M 50.71M
YoY Change -157.21% -54.32%
FREE CASH FLOW
Cash From Operating Activities -$24.09M -$32.64M
Capital Expenditures -$81.00K -$220.0K
Free Cash Flow -$24.01M -$32.42M
YoY Change -25.95% 65.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73640830
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61655867
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001479419
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73640830
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61655867
CY2022Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4002000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
4841000
CY2022Q1 dei Trading Symbol
TradingSymbol
KALA
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
72594005
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
65500275
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38150
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
KALA PHARMACEUTICALS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0604595
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1167 Massachusetts Avenue
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Arlington
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02476
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
996-5252
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
72594005
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65170000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
92136000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
4992000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2042000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13020000
CY2021Q1 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
991000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15345000
CY2022Q1 us-gaap Inventory Net
InventoryNet
10531000
CY2021Q4 kala Deferred Purchase Consideration Non Current
DeferredPurchaseConsiderationNonCurrent
883000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8639000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4542000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6204000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
98255000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
124366000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2704000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2722000
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
7801000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9578000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1385000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1299000
CY2022Q1 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
1429000
CY2021Q4 kala Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
1462000
CY2022Q1 us-gaap Assets
Assets
111574000
CY2021Q4 us-gaap Assets
Assets
139427000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6218000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4899000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21239000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20986000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
625000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
711000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3668000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3817000
CY2022Q1 kala Deferred Purchase Consideration Current
DeferredPurchaseConsiderationCurrent
1008000
CY2021Q4 kala Deferred Purchase Consideration Current
DeferredPurchaseConsiderationCurrent
7009000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
32758000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37422000
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
737000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
548000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
79361000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
78929000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
84100000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
85201000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Liabilities
Liabilities
116858000
CY2021Q4 us-gaap Liabilities
Liabilities
122623000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
72594005
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
65500275
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
73000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
66000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
569974000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
559126000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30412000
CY2022Q1 kala Other Comprehensive Income Available For Sale Securities Adjustments Net Of Tax Portions Attributable To Parent
OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentsNetOfTaxPortionsAttributableToParent
-2000
CY2021Q1 kala Other Comprehensive Income Available For Sale Securities Adjustments Net Of Tax Portions Attributable To Parent
OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentsNetOfTaxPortionsAttributableToParent
-1000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-575329000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-542388000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5284000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16804000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111574000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139427000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1372000
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3266000
CY2022Q1 kala Product Revenue Cost
ProductRevenueCost
775000
CY2021Q1 kala Product Revenue Cost
ProductRevenueCost
755000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26982000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27699000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4466000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3126000
CY2022Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
-1051000
CY2022Q1 kala Gain On Fair Value Re Measurement Of Contingent Consideration
GainOnFairValueReMeasurementOfContingentConsideration
988000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
32286000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
31580000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30914000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28314000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
43000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2035000
CY2021Q1 us-gaap Interest Expense
InterestExpense
2141000
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2027000
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2098000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32941000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30412000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73640830
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61655867
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32941000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32943000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30413000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16804000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
160000
CY2022Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
7936000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2756000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-32941000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5284000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.741
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0143
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0198
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
99995000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3822000
CY2022Q1 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-155000
CY2021Q1 kala Increase Decrease In Lease And Other Liabilities Noncurrent
IncreaseDecreaseInLeaseAndOtherLiabilitiesNoncurrent
-372000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24089000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32640000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1237000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
326000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 kala Stock Issued During Period Value New Issues At Market
StockIssuedDuringPeriodValueNewIssuesAtMarket
34709000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
431000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4886000
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-30412000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
109792000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-32941000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-30412000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
157000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
248000
CY2022Q1 kala Non Cash Operating Lease
NonCashOperatingLease
181000
CY2021Q1 kala Non Cash Operating Lease
NonCashOperatingLease
529000
CY2022Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
-1051000
CY2022Q1 kala Gain On Fair Value Re Measurement Of Contingent Consideration
GainOnFairValueReMeasurementOfContingentConsideration
988000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
432000
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
278000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2805000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4702000
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2000
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-10000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2325000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2602000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1662000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-373000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
164000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2809000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1222000
CY2022Q1 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
81000
CY2021Q1 kala Payments To Acquire Property Plant And Equipment And Other Assets
PaymentsToAcquirePropertyPlantAndEquipmentAndOtherAssets
219000
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4992000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
48250000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5073000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48031000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34709000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
163000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
615000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
154000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35315000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29008000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50706000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94878000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89756000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65870000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140462000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65870000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140462000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
700000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
12492000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65170000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127970000
CY2022Q1 kala Capital Expenditures Incurred But Not Yet Paid Accounts Payable
CapitalExpendituresIncurredButNotYetPaidAccountsPayable
174000
CY2021Q1 kala Capital Expenditures Incurred But Not Yet Paid Accounts Payable
CapitalExpendituresIncurredButNotYetPaidAccountsPayable
24000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1603000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1851000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
424000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1218000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-575329000
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
7935000
CY2022Q1 kala Gain Loss On Fair Value Re Measurement Of Deferred Purchase Consideration
GainLossOnFairValueReMeasurementOfDeferredPurchaseConsideration
-1051000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
719000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7090000
CY2022Q1 kala Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
18332000
CY2021Q4 kala Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
18217000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q1 us-gaap Inventory Net
InventoryNet
10531000
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
7801000
CY2021Q4 us-gaap Inventory Net
InventoryNet
8639000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9578000
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4994000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4992000
CY2022Q1 kala Investments Contractual Maturity Term
InvestmentsContractualMaturityTerm
P1Y
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
1324000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1328000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
9739000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9799000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7269000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.88
CY2022Q1 kala Accrued Revenue Reserves
AccruedRevenueReserves
11692000
CY2021Q4 kala Accrued Revenue Reserves
AccruedRevenueReserves
10300000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4591000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6324000
CY2022Q1 kala Accrued Commercialization Cost
AccruedCommercializationCost
1626000
CY2021Q4 kala Accrued Commercialization Cost
AccruedCommercializationCost
2134000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1313000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
881000
CY2022Q1 kala Accrued Contract Manufacturing
AccruedContractManufacturing
979000
CY2021Q4 kala Accrued Contract Manufacturing
AccruedContractManufacturing
396000
CY2022Q1 kala Development Costs Current
DevelopmentCostsCurrent
504000
CY2021Q4 kala Development Costs Current
DevelopmentCostsCurrent
127000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
534000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
824000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21239000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20986000
CY2022Q1 kala Number Of Vehicles Leased
NumberOfVehiclesLeased
100
CY2022Q1 kala Vehicles Leased Term
VehiclesLeasedTerm
P3Y
CY2022Q1 us-gaap Line Of Credit
LineOfCredit
450000
CY2021Q4 us-gaap Line Of Credit
LineOfCredit
450000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
176000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1216000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
40000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
447000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
509000
CY2022Q1 us-gaap Lease Cost
LeaseCost
663000
CY2021Q1 us-gaap Lease Cost
LeaseCost
1725000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1584000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.022
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.026
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
80000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
80000000
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1814000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1927000
CY2022Q1 kala Debt Instrument Exit Fees Of Total Principal Payments Value
DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue
1175000
CY2021Q4 kala Debt Instrument Exit Fees Of Total Principal Payments Value
DebtInstrumentExitFeesOfTotalPrincipalPaymentsValue
856000
CY2022Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
79361000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
78929000
CY2022Q1 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
215172
CY2021 kala Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
215172
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3698408
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3698408
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.729
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2805000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4702000
CY2022Q1 us-gaap Purchase Obligation
PurchaseObligation
46802000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32941000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30412000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73640830
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61655867
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14089981
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11734550
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q1 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
3423000
CY2022Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
6190000
CY2022Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
6380000
CY2022Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
9370000
CY2022Q1 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
7028000
CY2022Q1 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
14411000
CY2022Q1 kala Minimum Contract Amount Percent
MinimumContractAmountPercent
0.75
CY2022Q1 kala Minimum Contract Amount Percent
MinimumContractAmountPercent
0.75

Files In Submission

Name View Source Status
0001558370-22-008970-index-headers.html Edgar Link pending
0001558370-22-008970-index.html Edgar Link pending
0001558370-22-008970.txt Edgar Link pending
0001558370-22-008970-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kala-20220331.xsd Edgar Link pending
kala-20220331x10q.htm Edgar Link pending
kala-20220331x10q_htm.xml Edgar Link completed
kala-20220331xex31d1.htm Edgar Link pending
kala-20220331xex31d2.htm Edgar Link pending
kala-20220331xex32d1.htm Edgar Link pending
kala-20220331xex32d2.htm Edgar Link pending
kala-20220331_cal.xml Edgar Link unprocessable
kala-20220331_def.xml Edgar Link unprocessable
kala-20220331_lab.xml Edgar Link unprocessable
kala-20220331_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending